A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Previously Untreated Locally Advanced HNSCC
Latest Information Update: 26 Apr 2023
At a glance
- Drugs MIT 001 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Acronyms MIT-001
- Sponsors MitoImmune Therapeutics
- 21 Apr 2023 Planned End Date changed from 30 Sep 2023 to 30 Apr 2024.
- 21 Apr 2023 Planned primary completion date changed from 30 Sep 2022 to 30 Apr 2024.
- 19 Nov 2021 Planned End Date changed from 30 Apr 2023 to 30 Sep 2023.